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Thyroid Cancer in Thyroid Nodules
Diagnosed Using Ultrasonography and 
Fine Needle Aspiration Cytology
Jen-Der Lin*
Ultrasound and fine needle aspiration cytology are advocated as first-line examinations
for the assessment of thyroid nodules. This review investigates the incidence of thyroid
cancer in thyroid nodules after ultrasonographic examination. Furthermore, patient char-
acteristics, histological patterns, and therapeutic results among patients who received
thyroid ultrasound and fine needle aspiration cytology are discussed. The incidence of
thyroid cancer in thyroid nodules, as detected by thyroid ultrasound, was found to range
from 7.9% to 32.7% depending on the selected population. The incidence of thyroid
cancer in thyroid nodules reported depends on the studied cohort, ethnic group, age,
sex and iodine intake. Radiation exposure is also an important factor. Of the 6,330
patients with thyroid nodules who underwent surgical treatment, benign lesions were
observed in 75.5% (4,782 cases) of the cases. Papillary thyroid carcinoma was observed
in 79.8% (1,236 cases) of the 1,548 malignant cases. The percentage of malignancy was
found to increase after the age of 50 in both men and women. A decrease in tumor size
correlated with decreased cancer mortality; however, the beneficial effects of a small
tumor size were not seen in older patients. Radiation-exposed populations and thyroid
nodules or thyroid cancer were major problems from the atomic bomb in World War II
and the Chernobyl nuclear accident. However, most occupational radiation exposure
studies have not illustrated this harmful effect of radiation. In summary, over the time
course in the diagnosis of thyroid cancer in nodules, there is a trend of decrease in tumor
size and increase in the patient’s age. The diagnosis and treatment of non-well-differentiated
thyroid cancer in ageing patients is a major obstacle that needs to be overcome in the
future.
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Introduction
The histological trends observed in thyroid cancers
diagnosed after surgical treatment include an increase
in the percentage of papillary thyroid carcinoma
and microcarcinoma (≤ 1.0 cm in diameter) and a
decrease in the percentage of follicular and anaplas-
tic thyroid carcinomas [1,2]. Wide application of
thyroid ultrasound and fine needle aspiration cytol-
ogy (FNAC) may help promote early diagnosis of
thyroid cancers [3]. On the other hand, difficulties
in the preoperative diagnosis of follicular thyroid
cancer by FNAC and rapid growth of non-well-
differentiated thyroid cancers may hamper the suc-
cess of early diagnosis [4]. High-resolution thyroid
ultrasonography is a sensitive and specific diagnostic
tool used in clinical evaluation and epidemiological
studies of nodular thyroid disease [5]. Ultrasound-
guided FNAC of the thyroid nodule can diagnose
most thyroid nodules and differentiate between
malignant and benign ones [6]. However, this ap-
proach has limitations with regard to the detection
of tumors less than 5 mm in size and the cytologi-
cal interpretation of cases involving regression and
microfollicular proliferation [7]. Another limitation of
applying ultrasound and FNAC for diagnosing thy-
roid nodules is that it cannot differentiate between
benign and malignant follicular neoplasms [8,9].
In this review, we investigated the efficacy of
thyroid ultrasound with FNAC in diagnosing thy-
roid cancer and the changing trends caused by the
popular use of these techniques. Furthermore, data
of thyroid nodule patients who underwent surgical
treatment after ultrasound and FNAC during a 23-
year period at a single medical center were analyzed.
The purpose of this investigation was to determine
the changes that have occurred in patient and can-
cer characteristics over this period and the results
of therapy among the different cancer groups.
Epidemiological Studies of Thyroid
Cancer in Thyroid Nodules
Epidemiological studies have demonstrated a rela-
tively high frequency of thyroid diseases, including
thyroid nodules, among middle-aged females [10].
Previous studies have found that 1.3–4% of malig-
nancies presenting in the thyroid nodule are diag-
nosed using FNAC [11,12]. During the last 15 years,
popular use of thyroid ultrasound and improved
detection rates with new high-resolution machines
have increased the diagnostic rate of thyroid nod-
ules [13–16]. The presence of thyroid nodules in
over 50% of the studied cohort is not unusual [15].
In contrast, the incidence of thyroid cancer in histo-
logically proven thyroid nodules is variable depend-
ing on the surgical indication at different centers
[17–20]. Increased incidences of thyroid cancer
have been reported in recent years [21–23]; this
could be attributed to the application of thyroid
ultrasound and histological reports on thyroid micro-
carcinoma [24,25]. Table 1 [14,17–20,26] shows
the incidence of thyroid cancer in the different re-
gions of the world. The incidence of thyroid cancer
in thyroid nodules, as detected by thyroid ultra-
sound, was found to range from 7.9% to 32.7%
depending on the selected population. Consensus
and evidence-based practice for the management
of thyroid nodules was recently reported by the
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Table 1. Incidence of thyroid cancer in thyroid nodules after ultrasonographic examination [14,17–20,26]
No. of cases Malignancy (%) Characteristics Region Reference no.
1 2,338 11 Thyroid nodule Boston, USA 14
2 278 7.9 Metabolic syndrome Ankara, Turkey 17
3 658 12 Thyroid nodule Seoul, Korea 18
4 1,985 14.8/14.9 Single/multiple nodules Boston, USA 19
5 108 17.6 Solitary nodule Lodz, Poland 20
6 52 32.7 Children, adolescent Melbourne, Australia 26
American Thyroid Association [27]. The persons who
have undergone thyroid nodule operations and
the incidence of thyroid cancer in thyroid nodules
varies among the different regions. The incidence
of thyroid cancer in thyroid nodules depends on
the studied cohort, ethnic group, age, sex, and
iodine intake. Furthermore, radiation exposure is
also an important factor.
Data From Hospital-based Studies in
Taiwan
A previous study [28] of 3,846 thyroidectomies
retrospectively analyzed in Taiwan demonstrated
different indications for surgery including proven
malignancy (9%), suspicious malignancy (30%), evi-
dent compression symptoms (20%), hyperthyroid-
ism (20%), and cosmetic reasons (12%). Complete
pathology reports for the thyroidectomized speci-
mens were available in only 65% of the cases. For the
identification of thyroid cancer in thyroid nodules
in this area, data were analyzed in one institution
to identify the thyroid cancers in the thyroid nod-
ules after ultrasonographic examination in Taiwan.
A retrospective analysis performed on patient data
recorded from January 1986 to December 2007
revealed that 39,884 patients complaining of neck
nodules (mean age: 44.3 ± 14.7 years, range: 1
month to 93 years) received thyroid ultrasonogra-
phy and FNAC examinations at the Chang Gung
Medical Center in Linkou, Taiwan. A total of 6,330
patients (15.9%) underwent surgical treatment up
to the end of 2008. These patients included 5,292
women (mean age: 43.2 ± 13.9 years) and 1,038
men (mean age: 46.7 ± 14.9 years; p < 0.05).
Thyroid ultrasonography and FNAC were per-
formed in suspected thyroid nodules using 22-
gauge needles without local anesthesia. The aspirates
were placed on glass slides, air dried, and then
stained using the Romanowsky-based method from
Lin et al [29]. All ultrasonographic and cytological
results were interpreted by physicians at the Meta-
bolism Division of Chang Gung Medical Center.
A satisfactory smear was defined by the presence
of at least six clusters, each comprising at least 20
epithelial cells under a high-power field. Aspiration
cytology was immediately repeated for unsatisfac-
tory smears. Cases displaying easy bleeding during
FNAC along with the persistence of unsatisfactory
smears after 2–3 aspirations were classified as benign,
otherwise, surgery was suggested.
On the basis of the results of aspiration cytology,
the cases were categorized as malignant lesions,
follicular neoplasms, or benign lesions [30]. Surgery
was proposed for malignant and indeterminate
cases and for patients with compressive symptoms.
Patients diagnosed with benign nodules were asked
to undergo both 3- and 6-month follow-ups. Most
patients with benign masses who received surgery
did so for cosmetic reasons or because of the pres-
ence of tumors larger than 2.5 cm. Repeat ultra-
sonographic and FNAC examinations during the
study period were sorted based on chart numbers
and registered as individual cases. The patient’s age
on the final examination date was also recorded.
Pathological review was performed for all thyroid
carcinomas using the World Health Organization
classification [31]. For further analysis of the data,
well-differentiated thyroid cancers were categorized
as papillary, follicular, medullary, or Hürthle cell car-
cinomas. The other histological types were catego-
rized as non-well-differentiated thyroid cancer.
Of the 6,330 persons with thyroid nodules 
who underwent surgical treatment, the mean age
of men was higher than that of women, and the
peak age distribution was from 41 to 50 years in
both sexes (Fig. 1). According to the distribution
curves of the final histopathological results for
both sexes, the percentage of malignancy greatly
increased after the age of 51 years in both genders.
Male patients demonstrated a significantly higher
incidence of thyroid cancer than females in the 
41–50 and 61–70 age groups. There was a decrease
in surgical treatment and an increase in the ratio of
malignancy after the age of 50 (Fig. 1). Table 2 shows
the final histopathologic results of all 6,330 cases.
Benign lesions were observed in 75.5% (4,782 cases)
of all cases. Papillary thyroid carcinomas were obser-
ved in 79.8% (1,236 cases) of the 1,548 malignant
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Fig. 1. Age, sex distribution, percentage of operation in different age groups, and percentage of malignancy in 6,330 persons with thy-
roid nodules who underwent surgical treatment. *p < 0.01, †p < 0.05 when comparing males and females in different age groups. 
Table 2. Histopathological results, mean age and sex distribution of 6,330 patients with thyroid nodules who
underwent ultrasonography with fine needle aspiration cytology before thyroidectomy
Total Female/male Female Male
Pathology
No. Mean age (SD) no. (ratio) mean age (SD) mean age (SD)
Benign 4,782 43.5 ± 13.6 4,053/729 (5.6) 43.1 ± 13.4 45.9 ± 14.4*
Nodule hyperplasia 3,905 43.9 ± 13.4 3,319/586 (5.7) 43.4 ± 13.2 46.6 ± 13.9
Follicular adenoma 599 40.6 ± 14.0 498/101 (4.8) 40.2 ± 13.6 42.6 ± 16.0
Hürthle’s cell adenoma 155 47.2 ± 14.9 131/24 (5.5) 46.7 ± 15.7 50.0 ± 10.0
Thyroiditis 92 44.7 ± 14.7 80/12 (6.7) 45.6 ± 13.6 37.8 ± 19.8
Atypical 31 35.4 ± 13.4 25/6 (4.2) 35.6 ± 13.0 34.5 ± 16.5
Malignant 1,548 44.4 ± 15.5 1,239/309 (4.0) 43.5 ± 15.3 48.4 ± 15.9*
Papillary 1,236 43.9 ± 14.2 1,010/226 (4.5) 42.2 ± 14.1 45.8 ± 14.6*
Follicular 157 44.1 ± 17.6 129/28 (4.6) 43.2 ± 17.4 48.1 ± 18.5*
Medullary 31 44.7 ± 15.8 23/8 (2.9) 42.6 ± 16.0 50.9 ± 14.4*
Hürthle’s 21 52.4 ± 15.1 19/2 (9.5) 53.2 ± 15.7 45.5 ± 5.0
Anaplastic 45 67.1 ± 10.7 26/19 (1.4) 69.0 ± 10.8 64.6 ± 10.3
Metastasis 33 58.8 ± 15.8 17/16 (1.1) 56.5 ± 16.4 61.3 ± 15.4
PDTC 5 46.6 ± 25.1 3/2 (1.5) 50.0 ± 26.6 41.5 ± 31.8
Lymphoma 20 61.4 ± 18.3 12/8 (1.5) 63.8 ± 17.3 57.9 ± 20.4
Total 6,330 43.8 ± 14.1 5,292/1,038 (5.1) 43.2 ± 13.9 46.7 ± 14.9*
*p < 0.05 between males and females. PDTC = poorly differentiated thyroid cancer.
cases. The mean age of patients with malignant
lesions was not significantly different from that of
patients with benign lesions (44.4 ± 15.5 years vs.
43.5 ± 13.6 years; p > 0.05). Male thyroid cancer
patients were significantly older than female thy-
roid cancer patients (48.4 ± 15.9 years vs. 43.5 ±
15.3 years; p < 0.05). Among patients with papil-
lary, follicular and medullary thyroid carcinomas,
males were significantly older than females.
Of the surgically proven thyroid nodule cases,
the percentages of malignant cases among the
total surgical cases and percentages of thyroid
microcarcinoma and follicular thyroid cancer cases
from among the total thyroid cancer cases are
shown in Fig. 2. The results showed that the ratio
of malignant cases to total cases increased, while
the ratio of follicular to total thyroid cancer cases
decreased. Follicular thyroid carcinoma was found
to be present in less than 10% of the malignant
cases after 1999. Approximately 30% of the surgical
cases involved malignancy, with 23.2% of thyroid
microcarcinoma cases confirmed during the final
3-year period. The ratio of non-well-differentiated
to well-differentiated thyroid cancer decreased over
the time course of this study.
Of the 1,548 patients with thyroid cancer who
underwent the final histopathologic examination,
well-differentiated thyroid cancers were diagnosed
in 93.3% of the patients (1,445 patients). Fig. 3
demonstrates the mean tumor size of the well-
differentiated and non-well-differentiated thyroid
cancers according to the surgical diagnostic periods.
The curves representing tumor size in Fig. 3 were
obtained after excluding the microcarcinoma cases.
The curves representing the size of the non-well-
differentiated thyroid cancers had similar distribu-
tions. In contrast, the presence of microcarcinomas
influenced the mean tumor size of well-differentiated
thyroid cancers. These curves demonstrated a de-
crease in tumor size from 6.9 cm to 4.1 cm in non-
well-differentiated thyroid cancers and from 3.5 cm
to 2.8 cm in well-differentiated thyroid cancers.
Fig. 4 indicates the age of the patients at the first
operation when thyroid cancers were diagnosed.
Thyroid cancer patients were categorized into
well-differentiated and non-well-differentiated can-
cer groups. Both groups exhibited an increase in the
mean age at which thyroid cancer was diagnosed.
This tendency was more prominent for the non-well-
differentiated thyroid cancer group. The curves in
Fig. 5 illustrate the percentage of thyroid cancer,
non-well-differentiated thyroid cancer, advanced
tumor, node, metastasis (TNM) stages 2 to 4, and
thyroid cancer-specific mortality among the differ-
ent age groups and sexes. These curves showed
that after the age of 51–60 years, the percentages of
malignancy, non-well-differentiated thyroid cancers
and cancer mortality was greatly increased. In
addition, the percentages of malignancy, non-well-
differentiated thyroid cancers, cancer mortality and
advanced TNM stages were higher in males than
in females. Distant metastasis was observed at the
time of operation in 4.2% and 83.3% of well-
differentiated and non-well-differentiated thyroid
cancer cases, respectively. Cancer mortality was
observed in 5.1% (74/1,445 cases) and 69.9%
(71/103 cases) of the well-differentiated and non-
well-differentiated thyroid cancer cases, respectively,
after a mean follow-up period of 7.9 ± 0.1 years
(Table 3).
Most patients in whom malignant nodules were
suspected or diagnosed following FNAC underwent
surgical treatment. It has been shown recently that
the size of the thyroid nodule is not an important
factor for the determination of malignancy [32].
Nevertheless, in this retrospective analysis, the malig-
nant tumors of non-well-differentiated thyroid can-
cers were larger than those in well-differentiated
cancers. Many factors determine the tumor size in
patients with thyroid cancer who undergo subse-
quent surgical treatment. The main factors include
earlier detection by examination, higher socio-
economic status, and the preference of the patient
and surgeon. Larger tumors observed among non-
well-differentiated thyroid cancers might be one of
the reasons for the faster growth of these tumors
relative to well-differentiated thyroid cancers.
Age and gender are important factors for deter-
mining cancer survival [33]. According to a recent
report, gender has an age-specific effect on the
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Fig. 2. (A) Percentages of malignant cases among the total surgical cases and thyroid microcarcinoma (TMC) and follicular 
thyroid cancer cases among the total thyroid cancer (TCA) cases from 1986 to 2007 expressed in 3-year periods. (B) Anaplastic,
and non-well-differentiated to well-differentiated tumor ratios.
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Fig. 3. Mean tumor size of well-differentiated
thyroid cancers and non-well-differentiated
thyroid cancers, including or excluding micro-
carcinoma cases according to the year diag-
nosed.TCA = thyroid cancer, TMC = thyroid
microcarcinoma.
Fig. 4. Mean age of patients at the time 
of the first thyroid operation during which 
thyroid cancer was diagnosed among well-
differentiated and non-well-differentiated can-
cer groups.
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incidence of thyroid cancer [34]. During last 20
years, the number of patients with thyroid cancer
has increased, especially for non-well-differentiated
thyroid cancers. Age is an independent prognostic
factor for differentiated thyroid cancers [35]. The
series [35] illustrated that the percentage of ma-
lignancy was increased after the age of 50 in 
both men and women. The rapid growth rate of
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Fig. 5. Percentages of malignancy, non-well-differentiated thyroid cancer (TCA), cancer mortality, and advanced TNM stages
among the different age groups of (A) females and (B) males.
non-well-differentiated thyroid cancers is a major
hurdle that must be overcome. The prevalence of
malignancy has been demonstrated in patients at
both extremes of age (i.e. < 30 years and > 80 years)
[36]. However, we did not observe an increased
prevalence of thyroid malignancy in the younger
age groups for either female or male patients. The
decrease in the percentage of patients who under-
went surgical treatment after the age of 50 may be
due to the increased ratio of non-well-differentiated
thyroid cancers with a poor prognosis. Histopatho-
logic patterns consistent with metastatic cancer or
lymphoma of the thyroid were not indications for
surgical treatment. However, further studies are
required to determine the possibility of delayed
surgical intervention or conservative therapeutic
modality in ageing patients with thyroid neoplasms.
Age, tumor size and the presence of extrathy-
roidal invasion are deemed more important for
accurate prognosis than histology in papillary and
follicular thyroid cancers [37]. Comparison of iodide
intake among different populations may not corre-
spond to the different histologic patterns of thyroid
cancer, as demonstrated in transverse section stud-
ies [38,39]. In a longitudinal, long-term observa-
tional study, the percentage of follicular thyroid
cancer was found to be decreased after the success-
ful control of endemic goiter [40]. With regard to
thyroid cancer tumor size, a recent study indicated
an increased incidence of papillary thyroid micro-
carcinomas [41]. Of these papillary microcarcinoma
cases, 37.6% were diagnosed postoperatively with
excellent prognosis [2]. Mean tumor size in cases
of well-differentiated thyroid cancers has decreased
during the last two decades, even after the exclu-
sion of thyroid microcarcinoma cases, which im-
proved the overall prognosis of this group.
Recent studies have shown that the increase in
papillary carcinoma rates is due to increasing rates
of microcarcinoma, with a 30% increase due to
cancers 1.1–2 cm in diameter and a 20% increase
due to cancers > 2 cm in diameter [42,43]. The inci-
dence of thyroid cancer has increased; however,
tumor size has decreased for both well-differentiated
and non-well-differentiated thyroid cancers. This
tendency persists even when the microcarcinoma
cases are excluded. A decrease in tumor size is cor-
related with decreased cancer mortality; however,
the beneficial effects of small tumor size are not
seen in older patients.
Thyroid nodules were observed predominantly
in females, with a ratio of 5.1 to 1 (Table 2).
Among patients with thyroid nodules, the inci-
dence of malignancy was higher in males than in
females (29.77% vs. 23.41%). In addition, among
the thyroid cancer patients, the ratio of non-well-
differentiated thyroid cancers was higher among
males than in females (13.9% vs. 4.7%). These
results led us to conclude that the incidence of
thyroid cancer in patients with thyroid nodules is
higher in males than in females. Additionally, the
prognosis of thyroid cancer is also poorer in males
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Table 3. Characteristics of non-well-differentiated and well-differentiated thyroid carcinoma groups*
Non-well (n = 103) Well (n = 1,445) Total p
Age 62.4 ± 15.5 43.2 ± 14.7 44.4 ± 15.5 0.0001
Sex (F/M) 58/45 1,181/264 1,239/309 0.0001
Tumor size (cm) 5.4 ± 0.2 2.6 ± 0.1 2.8 ± 0.1 0.0001
Soft tissue invasion 8 (7.8) 260 (18.0) 268 (17.3) NA
Lymph node metastasis 2 (1.9) 163 (11.3) 165 (10.7) NA
Distant metastasis 86 (83.5) 61 (4.2) 147 (9.5) NA
Recurrence 85 (83.3) 217 (15.1) 302 (19.6) 0.0001
Follow-up period (yr) [median] 2.6 ± 0.4 [0.6] 8.2 ± 0.19 [7.6] 7.9 ± 0.1 [7.0] 0.0001
Mortality 71 (68.9) 74 (5.1) 145 (9.4) 0.0001
*Values are mean ± SD or n (%) except for sex. NA = not available.
[36]. With regard to well-differentiated thyroid can-
cer, our data revealed that the incidence of papil-
lary thyroid cancer was very similar in both sexes
(85.5% in females and 85.6% in males). Because of
the excellent prognosis of papillary thyroid cancer,
the prognosis of well-differentiated thyroid cancers
may not be statistically different between the sexes
[44]. In contrast, further investigation of local neck
invasion and distant metastasis of papillary thyroid
cancers may reveal an independent risk factor in
males [45,46].
Anaplastic thyroid cancer and metastatic can-
cer of the thyroid are the main categories of non-
well-differentiated thyroid cancer, and the prognosis
is poor for both of these cancer types [47,48]. The
histological pattern of metastatic cancer of the
thyroid depends on geographic and ethnic charac-
teristics; however, most metastatic cancers of the
thyroid represent the terminal status of a primary
cancer.
Radiation-exposed Persons Screening
for Thyroid Nodules and Cancer
There is a high risk of developing thyroid cancer in
thyroid nodules in persons exposed to radiation from
sources of those used for therapeutic purposes or due
to nuclear fallout [49–51]. The role of ultrasound in
irradiation-exposed patients and how it has changed
over time has been evaluated [52]. Thyroid nod-
ules are extremely common in irradiated persons.
Furthermore, many new nodules are observed over
time, but most are small and detectable because of
the increased resolution of ultrasound machines.
FNAC of all thyroid nodules in irradiated patients is
not feasible, and ultrasound is useful in identifying
those lesions that are growing. Ultrasonographic
data concerning radiation-exposed persons with
thyroid nodules and cancer include three main fields:
the atomic bomb in World War II, the Chernobyl
nuclear accident, and epidemiological studies in
radiation-exposed high-risk persons.
Based on a prospective study by the Nagasaki
Radiation Effects Research Foundation that 
comprised 2,637 atomic bomb survivors from
1984 through 1987 as identified by ultrasonogra-
phy, the hazards ratio for cancer development was
significantly higher at 23.6 (95% confidence inter-
val [CI] = 7.6–72.8) in the solid nodule group in
comparison with the nodule-free group [53]. Thyroid
cancer did not significantly increase in the cystic
group. Compared with the Chernobyl nuclear acci-
dent, there was less data from the thyroid ultra-
sonographic screen in atomic bomb survivors. Data
obtained from autopsy cases between 1950 and
1985 showed that latent thyroid cancer was detected
in 3.5% (2.5% for males and 4.5% for females) of
the 4,425 cases [54]. The relative risk in cases who
had an absorbed radiation dose over 50 rad
(0.5 Gy) was 1.7 for males (not significant) 2.0 for
females (p ≤ 0.05) and 1.9 for both sexes combined
(p ≤ 0.05) compared with controls. A significant
linear radiation dose response for thyroid nodules,
including malignant tumors and benign nodules,
has been found in atomic bomb survivors. In con-
trast, there is no significant dose response for
autoimmune thyroid diseases [50]. The long-term
prognosis of these thyroid nodule cases with ultra-
sonographic data indicates that the risk of thyroid
cancer development is high in atomic bomb sur-
vivors with solid thyroid nodules [53].
There is a great amount of clinical information
concerning the epidemiology, thyroid ultrasonog-
raphy, and histology data of thyroid cancers in
persons exposed to ionizing radiation from the
Chernobyl nuclear accident. These data include
the exposed population living around Chernobyl
[55,56], children 4–14 years of age exposed to
radioactive fallout [57], and persons exposed 
in utero to iodine-131 during the Chernobyl fallout
[58]. During the first 4.5 years after the Chernobyl
accident, the incidence, prevalence, and character-
istics of thyroid nodules were the same in population
samples from both highly contaminated and con-
trol settlements, and were similar to results reported
for unexposed populations in other countries [55].
A cohort of 32,385 individuals younger than 18
years of age, residing in the most heavily conta-
minated areas in the Ukraine at the time of the
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accident, that was invited to be screened for any thy-
roid pathology by ultrasonography and palpation
in 1998–2000 showed a relative risk of 5.25 per Gy
(95% CI = 1.70–27.5) [56]. An older age at exposure
was associated with a decreased risk of radiation-
related thyroid cancer. Comparison of the clinical
and pathological findings of surgically removed thy-
roid tumors in adults from the Chernobyl accident
showed that the percentage of the invasive form
of cancer (T4) was significantly higher in irradiated
patients than that of the nonirradiated patients
(39% vs. 23%; p < 0.05). A similar finding was also
observed for regional metastases (N1a,1b) (41% vs.
19%; p < 0.01) and the frequency of multifocality
(33% vs. 24%; p < 0.05) [59]. Due to the high ratio
of the invasive type of multicentric thyroid cancers,
completion total thyroidectomy was recommended
for the treatment of recurrent thyroid cancer and
lung or lymph node metastases in 61% (11/18) of
the patients in whom residual differentiated thyroid
carcinoma was not previously recognized [60].
Thyroid nodules and thyroid cancer occur more
frequently in people exposed to radiation for ther-
apeutic purposes or through the environment
[49,61,62]. A cross-sectional study evaluated the
prevalence of thyroid nodules in radiation-exposed
workers compared with a stratified sample of non-
exposed workers. The prevalence of thyroid nodules
less than 1 cm in diameter in the exposed group
with a detectable dose was 11.28% in males and
9.68% in females, while in the exposed group with
an undetectable dose the prevalence was 10.39%
in males and 16.67% in females. The prevalence of
thyroid nodules larger than 1 cm was significantly
different in exposed and nonexposed health staff
(males: 18.68% nonexposed vs. 3.76% exposed;
females: 20.30% nonexposed vs. 3.23% exposed).
Occupational exposure to radiation combined with
mild iodine deficiency did not increase the risk of
developing thyroid nodules. The significantly higher
prevalence of thyroid nodules in the nonexposed
group could be explained by the high percentage
(22%) of people with a familial history of thyroid
disease [49]. The detection of thyroid nodules is ex-
tremely common in the conventional use of external
radiation for benign conditions of the head and neck
area prior to 16 years of age [52,63,64]. Many new
thyroid nodules may be observed over time and
long-term follow-up by ultrasound with FNAC is rec-
ommended. The mean latency period for benign
tumors was longer than that for malignant lesions
(mean, 34.1 years and 28.4 years, respectively) in
one long-term follow-up study [63]. A previous study
[65] on cancer risks in a population that received pro-
longed low dose-rate gamma-irradiation for approx-
imately 10 years as a result of occupying buildings
containing 60Co-contaminated steel in Taiwan
showed a marginally significant risk for thyroid can-
cers in women (n = 6, standardized incidence ratios
2.6, 95% CI = 1.0–5.7). Periodic long-term follow-
up of thyroid disorders by ultrasonography on per-
sons with a history of radiation exposure has been
recommended in most epidemiological studies.
Recommendation for Thyroid Nodules
Thyroid nodules with a maximum diameter greater
than 1 cm should be evaluated because they have
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Thyroid nodule(s)
Cystic
Ultrasound and FNAC
Cytology
Solid/mixed
> 1 cm§
Anti-TPO
Suspicious BenignMalignant
Scan*Surgery> 3 cm Follow up
Scan*
TSH (or Free T4)
Repeat
aspiration
L-T4 treat*
Fig. 6. Recommendations for the evaluation of patients with
thyroid nodules. *Optional if no contraindication; §unless sign 
of malignancy. FNAC = fine needle aspiration cytology; TSH =
thyroid-stimulating hormone; TPO = thyroid peroxidase.
a greater potential to be clinically significant carci-
nomas. Nodules less than 1 cm in diameter with
suspicious ultrasound findings or associated lym-
phadenopathy, a history of head and neck irradia-
tion, or a family history of thyroid cancer require
evaluation. Fig. 6 shows the recommendations for
thyroid nodules in Taiwan. Subclinical thyroid dys-
function was not easily detected in the aged popu-
lation. Thyroid-stimulating hormone screening as
an indicator of thyroid function was found to be
effective. For large thyroid cysts (> 3 cm) and per-
sistent or recurrent cyst after aspiration, surgical
treatment has been recommended in evidence-
based studies [66,67]. Partial cystic degeneration
of the thyroid nodules with hypoechoic lesions in
solid parts or microcalcification are also indicated
for surgical treatment.
Conclusions
Approximately 25% of the operative thyroid nodules
after ultrasonographic examination turn out to be
thyroid cancer. Thus, thyroid ultrasonography with
FNAC is a cost effective way of managing thyroid
nodules in Taiwan.
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